Radiation Safety Guidelines for Radioimmunotherapy With Yttrium 90 Ibritumomab Tiuxetan

Carolyn Hendrix, RN, OCN®

Radioimmunotherapy is a new cancer therapy that combines the cytotoxicity of radiation with the tumor-specific targeting of monoclonal antibodies. Yttrium 90 (Y-90) ibritumomab tiuxetan (Zevalin®, IDEC Pharmaceuticals Corporation, San Diego, CA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma (NHL), including patients with rituximab-refractory follicular NHL. Y-90 ibritumomab tiuxetan requires only universal safety precautions and does not impose undue risks or radiation safety restrictions on patients or healthcare workers. The ibritumomab tiuxetan regimen can be administered safely in an outpatient setting. Nurses should become familiar with the necessary precautions in caring for patients treated with Y-90 ibritumomab tiuxetan, both to educate patients about safety issues and to minimize the risk of radiation exposure to staff and others.

Key Words: radioimmunotherapy, safety

Radioimmunotherapy is a new cancer therapy that combines the cytotoxicity of radiation with the tumor-specific targeting of monoclonal antibodies. Yttrium 90 (Y-90) ibritumomab tiuxetan (Zevalin®, IDEC Pharmaceuticals Corporation, San Diego, CA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma (NHL), including patients with rituximab-refractory follicular NHL. Y-90 ibritumomab tiuxetan requires only universal safety precautions and does not impose undue risks or radiation safety restrictions on patients or healthcare workers. The ibritumomab tiuxetan regimen can be administered safely in an outpatient setting. Nurses should become familiar with the necessary precautions in caring for patients treated with Y-90 ibritumomab tiuxetan, both to educate patients about safety issues and to minimize the risk of radiation exposure to staff and others.

Key Words: radioimmunotherapy, safety

Carolyn Hendrix, RN, OCN®

Submitted June 2003. Accepted for publication August 29, 2003. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Oncology Nursing Society.) Carolyn Hendrix, RN, OCN®; is a member of the IDEC Speakers’ Bureau. IDEC Pharmaceuticals Corporation is the manufacturer of Zevalin™ (yttrium 90 ibritumomab tiuxetan). Digital Object Identifier: 10.1188/04.CJON.31-34
not express the antigen being targeted) (Illidge & Johnson, 2000).

**Safety Guidelines for Radioimmunotherapy**

Radiation safety focuses on three key areas: using appropriate shielding during administration, minimizing exposure time, and maximizing distance from the radiation source. Determining the appropriate material and thickness for shielding depends largely on the type of radiation emitted by the radionuclide. Most oncology nurses are familiar with the radionuclide iodine 131, which typically has been used to treat thyroid disease. Iodine 131 emits gamma radiation, and in most instances, its use requires patient isolation, lead shielding during administration, and strict safety precautions after patient discharge. The ibritumomab tiuxetan regimen, however, uses the radionuclide Y-90, which is a pure beta emitter. Therefore, fewer precautions are necessary when using this agent.

**Yttrium 90**

**Ibritumomab Tiuxetan**

Y-90 ibritumomab tiuxetan consists of ibritumomab, a murine monoclonal antibody to the CD20 antigen stably bound to tiuxetan, which chelates the radionuclide Y-90 (see Figure 1). Ibritumomab is the parent of the chimeric monoclonal antibody rituximab. In clinical trials, Y-90 ibritumomab tiuxetan has produced overall response rates of 73%–83% in indolent, low-grade, or follicular NHL (Wiseman et al., 2002; Witzig, Emmanouilides, et al., 2003; Witzig, Flinn, et al., 2002; Witzig, Gordon, et al., 2002).

**Figure 1. Yttrium 90 Ibritumomab Tiuxetan**

Note. Reprinted with permission from IDEC Pharmaceuticals, Inc., San Diego, CA.

**Ibritumomab Tiuxetan Regimen**

The ibritumomab tiuxetan regimen is a single-treatment course that is given on two days approximately one week apart (IDEC Pharmaceuticals Corporation, 2002) (see Figure 2). On the first day of the ibritumomab tiuxetan regimen, the patient is given an infusion of rituximab 250 mg/m², followed within four hours by a tracer dose of indium 111 ibritumomab tiuxetan 5 mCi (1.6 mg) injected slowly over 10 minutes. Whole body planar anterior and posterior view gamma images are obtained at 2–24 hours and 48–72 hours after this imaging dose of indium 111 ibritumomab tiuxetan to assess the biodistribution of the tracer dose; an optional third image can be obtained at 90–120 hours to resolve any ambiguities. If the biodistribution is as expected, on regimen days 7, 8, or 9, the therapeutic dose of Y-90 ibritumomab tiuxetan (0.4 mCi/kg if the patient’s platelet count is ≥ 150,000/mm³ or 0.3 mCi/kg if the patient’s platelet count is 100,000–149,000/mm³) is injected slowly over 10 minutes and again within four hours after the administration of rituximab 250 mg/m². The maximum dose of Y-90 ibritumomab tiuxetan is 32 mCi (IDEC Pharmaceuticals Corporation).

Nurses play a key role in coordinating rituximab infusions given before the imaging and therapeutic doses of radioimmunoconjugate. These rituximab infusions are given to improve the biodistribution of the Y-90 ibritumomab tiuxetan to the tumor sites. The predose of rituximab binds to readily accessible CD20 sites on cells in the peripheral blood and prevents indiscriminate uptake of the radio-labeled antibody in the reticuloendothelial system (Wagner et al., 2002). Nurses also are integral in providing patient care throughout the regimen of ibritumomab tiuxetan administration. Before treatment is initiated, nursing staff will be involved in counseling patients, obtaining insurance authorization, and educating patients and their families and caregivers about radiation safety and follow-up care. Coding and reimbursement information, which was revised in 2003, is available online at www.zevalin.com/pdfs/Billing_Guide.pdf. In addition, IDEC Pharmaceuticals Corporation offers a reimbursement assistance program, RESULTS™ for Zevalin, which provides assistance with reimbursement and coding issues as well as programs for the uninsured (800-386-9997, phone; 800-513-8055, fax; www.zevalin.com/html/HealthcareProfessionals/Reimbursement/results.html, Web site).

**Safety of Yttrium 90 Ibritumomab Tiuxetan**

Y-90 emits only beta radiation, which has a mean effective path length of approximately 5 mm in soft tissue (i.e., 90% of the energy is absorbed within a sphere with a radius of 5 mm), and because of this, it does not penetrate outside the patient’s body. This form of radiation is absorbed by approximately 1 cm of acrylic; therefore, fewer safety precautions are required in using Y-90 ibritumomab tiuxetan than in using radionuclides such as iodine 131 that emit gamma rays (Wagner et al., 2002). Beta emissions pose minimal radiation hazards to healthcare workers or patients’ contacts; as a result, the ibritumomab tiuxetan regimen can be administered on an outpatient basis using only universal precautions for radiation safety. Acrylic shielding is required (acrylic vial and syringe shields are available [see Figure 3]), and patient isolation is unnecessary (see Figure 4). Lead shielding...
Implications for Practice

The ibritumomab tiuxetan regimen presents oncology nurses with new opportunities for collaboration and education. Because of regulatory, safety, and administrative requirements, RIT necessitates a multidisciplinary approach among oncology nurses, oncology physicians, nuclear medicine and radiation therapy personnel, radiopharmacists, and radiation safety officers. In this team approach, oncology nurses play a key role in ensuring continuity throughout the treatment and, because they are the members of the team with the most direct and ongoing contact with patients, they are in a unique position to counsel patients, families, and caregivers, as well as educate them about the various aspects of cancer care (Volker, 1992), including the precautions necessary to prevent radiation exposure to others during and after Y-90 ibritumomab tiuxetan treatment.

Because many patients with NHL who are treated with RIT already have been treated with several other therapies, nurses must educate patients about the differences between RIT and traditional cancer therapies.

Most patients who are treated with Y-90 ibritumomab tiuxetan are outpatients. Therefore, the nursing staff at outpatient facilities must be trained in radiation safety. Many nuclear medicine or radiation therapy departments are licensed to administer RIT. Most nursing staff members will not be involved directly in administering the radiolabeled components of the ibritumomab tiuxetan regimen, but they should be familiar with safety guidelines. Nurses typically are responsible for administering infusions of rituximab, and they also may assist with patient care activities such as implanted port access or management of the side effects of monoclonal antibodies.

Nurses continually find themselves on the cutting edge of clinical practice. As modalities move from research to clinical practice, nurses must be familiar with new patient care requirements.

Table 1: Radiation Exposure

<table>
<thead>
<tr>
<th>Level of Exposure</th>
<th>Amount of Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest x-ray</td>
<td>~ 20 mrem</td>
</tr>
<tr>
<td>Average person in the United States</td>
<td>360 mrem/year</td>
</tr>
<tr>
<td>Average hospital radiation worker in the United States</td>
<td>+ 150 mrem/year (510 mrem/year total)</td>
</tr>
<tr>
<td>Radiation sickness from single dose</td>
<td>&gt; 100 rem</td>
</tr>
<tr>
<td>Immune system, vascular damage</td>
<td>&gt; 300 rem</td>
</tr>
</tbody>
</table>


References

Yttrium 90 (Y-90), the therapeutic radionuclide used with ibritumomab tiuxetan, is a pure beta emitter that poses fewer risks to patients, caregivers, and healthcare staff than conventional radionuclides (e.g., iodine 131), which emit both beta and gamma radiation.

The ibritumomab tiuxetan regimen is a single-treatment course that is given on two days approximately one week apart.

Universal safety precautions apply with Y-90 ibritumomab tiuxetan therapy.

For the first three days after treatment, patients should be instructed to clean any spilled urine, properly dispose of any materials contaminated with body fluids, and wash their hands thoroughly after using a toilet.

Family members and friends need to be reassured that close contact with the patient is not harmful. Minimal radiation exposure, which is in the range of everyday background radiation, is associated with this treatment.

Continuing education credit for this and other CJON articles is available in the Publications area of www.ons.org.

For more information on this topic, visit the following Web sites.

American Cancer Society: Yttrium 90 Ibritumomab Therapy
www.cancer.org/docroot/CDG/content/CDG_90_yttrium_(90Y)_ibritumomab_tiuxetan.html

Radiation Safety Academy
www.radtrain.com

Links can be found at www.ons.org.